190 related articles for article (PubMed ID: 31699528)
1. Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection.
Lafin JT; Singla N; Woldu SL; Lotan Y; Lewis CM; Majmudar K; Savelyeva A; Kapur P; Margulis V; Strand DW; Murray MJ; Amatruda JF; Bagrodia A
Eur Urol; 2020 Feb; 77(2):290-292. PubMed ID: 31699528
[No Abstract] [Full Text] [Related]
2. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
Spiekermann M; Belge G; Winter N; Ikogho R; Balks T; Bullerdiek J; Dieckmann KP
Andrology; 2015 Jan; 3(1):78-84. PubMed ID: 25187505
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
Konneh B; Lafin JT; Howard J; Gerald T; Amini A; Savelyeva A; Woldu SL; Lewis CM; Jia L; Margulis V; Coleman N; Scarpini C; Frazier AL; Murray MJ; Amatruda JF; Bagrodia A
Andrology; 2023 May; 11(4):634-640. PubMed ID: 36254623
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of plasma miR-371a-3p in germ cell tumors.
Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ
J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846
[TBL] [Abstract][Full Text] [Related]
6. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G
J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280
[TBL] [Abstract][Full Text] [Related]
7. Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
Badia RR; Abe D; Wong D; Singla N; Savelyeva A; Chertack N; Woldu SL; Lotan Y; Mauck R; Ouyang D; Meng X; Lewis CM; Majmudar K; Jia L; Kapur P; Xu L; Frazier AL; Margulis V; Strand DW; Coleman N; Murray MJ; Amatruda JF; Lafin JT; Bagrodia A
J Urol; 2021 Jan; 205(1):137-144. PubMed ID: 32856980
[TBL] [Abstract][Full Text] [Related]
8. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
Beck SD; Foster RS; Bihrle R; Donohue JP
Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma.
Seelemeyer F; Pfister D; Pappesch R; Merkelbach-Bruse S; Paffenholz P; Heidenreich A
Eur Urol Oncol; 2024 Jun; 7(3):319-322. PubMed ID: 37932157
[TBL] [Abstract][Full Text] [Related]
10. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.
Terbuch A; Adiprasito JB; Stiegelbauer V; Seles M; Klec C; Pichler GP; Resel M; Posch F; Lembeck AL; Stöger H; Szkandera J; Pummer K; Bauernhofer T; Hutterer GC; Gerger A; Stotz M; Pichler M
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321995
[TBL] [Abstract][Full Text] [Related]
11. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.
Syring I; Bartels J; Holdenrieder S; Kristiansen G; Müller SC; Ellinger J
J Urol; 2015 Jan; 193(1):331-7. PubMed ID: 25046619
[TBL] [Abstract][Full Text] [Related]
12. Serum Levels of MicroRNA371a-3p: A Highly Sensitive Tool for Diagnosing and Staging Testicular Germ Cell Tumours: A Clinical Case Series.
Anheuser P; Radtke A; Wülfing C; Kranz J; Belge G; Dieckmann KP
Urol Int; 2017; 99(1):98-103. PubMed ID: 28586780
[TBL] [Abstract][Full Text] [Related]
13. microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients.
van Agthoven T; Eijkenboom WMH; Looijenga LHJ
Cell Oncol (Dordr); 2017 Aug; 40(4):379-388. PubMed ID: 28612337
[TBL] [Abstract][Full Text] [Related]
14. Desperation Postchemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Germ Cell Tumors.
Carver BS
Urol Clin North Am; 2015 Aug; 42(3):343-6. PubMed ID: 26216821
[TBL] [Abstract][Full Text] [Related]
15. Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors.
Nayan M; Jewett MA; Sweet J; Anson-Cartwright L; Bedard PL; Moore M; Chung P; Warde P; Hamilton RJ
J Urol; 2015 Aug; 194(2):386-91. PubMed ID: 25823792
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA miR-371a-3p - A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele Fluid.
Dieckmann KP; Spiekermann M; Balks T; Ikogho R; Anheuser P; Wosniok W; Loening T; Bullerdiek J; Belge G
Urol Int; 2016; 97(1):76-83. PubMed ID: 26989896
[TBL] [Abstract][Full Text] [Related]
17. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?
Radtke A; Cremers JF; Kliesch S; Riek S; Junker K; Mohamed SA; Anheuser P; Belge G; Dieckmann KP
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2383-2392. PubMed ID: 28819887
[TBL] [Abstract][Full Text] [Related]
18. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors.
Wood DP; Herr HW; Heller G; Vlamis V; Sogani PC; Motzer RJ; Fair WR; Bosl GJ
J Urol; 1992 Dec; 148(6):1812-5; discussion 1815-6. PubMed ID: 1331547
[TBL] [Abstract][Full Text] [Related]
19. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience.
Hyams ES; Pierorazio P; Proteek O; Sroka M; Kavoussi LR; Allaf ME
J Urol; 2012 Feb; 187(2):487-92. PubMed ID: 22177913
[TBL] [Abstract][Full Text] [Related]
20. Editorial comment on: laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.
Fornara P; Hoda MR
Eur Urol; 2008 Nov; 54(5):1015-6. PubMed ID: 18722706
[No Abstract] [Full Text] [Related]
[Next] [New Search]
